Tag - Corbus Pharmaceuticals

Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum and might be used to treat any fibrotic disease, including cystic fibrosis (CF), the company announced in a press release. Read more >>

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in October. Read more >>

Corbus Pharmaceuticals receives Orphan Designation for lenabasum for the treatment of DM in EU

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals announces that the European Commission has granted Orphan Designation in the European Union (EU) to lenabasum, its synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis (DM). Read more >>

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology (“ACR”) 2018 Annual Meeting being held October 19-24, 2018 in Chicago, Illinois. Read more >>

Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at the Annual B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at 9:25 a.m. EDT in New York, NY. Read more >>

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis (“DM”). Dermatomyositis is a rare and serious multisystem inflammatory autoimmune disease affecting muscle and skin. The U.S. Food and Drug Administration (“FDA”) provided guidance on the overall study design of this trial at a recent end-of-Phase 2 meeting....

Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Read more >>

Lenabasum Continues to Show Promise for Treatment of Systemic Sclerosis in Extension Study

Ziad2022-11-25T14:05:04-05:00Treatment with Corbus Pharmaceuticals’ investigative therapy lenabasum (formerly known as anabasum) significantly improves the symptoms of diffuse cutaneous systemic sclerosis in a Phase 2 open-label extension study. Read more >>

Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference

Ziad2022-11-25T14:05:04-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory diseases, announced that it will be presenting at the Resolution of Inflammation, Infection and Tissue Regeneration Conference in partnership with the New York Academy of Sciences (NYAS), taking place on Tuesday, June 26, 2018 in New York City. Read more >>

Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

Ziad2022-11-25T14:05:04-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that data from open-label extensions (OLEs) of its systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies are being presented at the Annual European Congress of Rheumatology (EULAR 2018). Read more >>